LataMed AI Corp. (OTC: LMEDD) announced that its 5-for-1 forward stock split became effective at the opening of trading today, following publication of the corporate action on the FINRA Daily List dated July 14, 2026. The company’s common stock will trade under the temporary symbol LMEDD for approximately 20 business days before reverting to LMED. The forward stock split is implemented in conjunction with a mandatory share exchange and a new CUSIP number, 21116R404, while the prior CUSIP, 21116R305, is suspended.
The move is designed to adjust the company’s capital structure as it pursues commercialization of its artificial intelligence platforms, including CardioAI, PulmoAI, and NeuroAI. Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated that the split represents an important corporate milestone and that the company looks forward to continuing execution of its long-term strategy focused on expanding its telemedicine platform and AI technologies.
Shareholders holding shares through brokerage accounts or in electronic book-entry form generally do not need to take any action, as brokerage firms and custodians are expected to process the corporate action automatically. Those holding physical stock certificates are not required to immediately surrender them, but when presented for transfer, sale, or exchange, they will be processed under the new CUSIP and exchanged for the appropriate number of post-split shares.
The forward stock split and share exchange are part of LataMed AI’s broader efforts to strengthen its financial positioning as a development-stage digital health and artificial intelligence technology company. The company focuses on building telehealth infrastructure, healthcare coordination tools, and AI-enabled solutions for emerging markets, with an initial regional focus on Latin America. Its platforms aim to support healthcare access, patient engagement, provider coordination, emergency medical response, pharmacy integration, insurance accessibility, payment solutions, and data-driven healthcare operations.
For investors, the corporate action may impact share price and liquidity, though the company emphasizes that the split itself does not change the underlying value of the business. The forward stock split reduces the number of outstanding shares proportionally, which could affect trading dynamics. The temporary “D” designation on the ticker symbol is a standard identifier used by FINRA for certain corporate actions and is expected to remain for about 20 business days.
LataMed AI encourages shareholders with questions to contact their brokerage firm or the company’s transfer agent. Additional information is available on the company’s website at https://latamed.ai and in its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
The company’s forward-looking statements in the press release indicate that actual results may differ materially due to risks such as the ability to implement its business plan, availability of financing, regulatory authorizations, operational execution, technology deployment risks, and general economic conditions. LataMed AI undertakes no obligation to update any forward-looking statements except as required by law.
This corporate action underscores LataMed AI’s commitment to advancing its AI-driven healthcare solutions in emerging markets, positioning the company for potential growth as it seeks to commercialize its technology platforms.
